Laboratorio Reig Jofre, S.A.

MCE RJF.MC

Laboratorio Reig Jofre, S.A. Revenue for the year ending December 31, 2023: USD 348.88 M

Laboratorio Reig Jofre, S.A. Revenue is USD 348.88 M for the year ending December 31, 2023, a 20.26% change year over year. Revenue is the total amount of money generated from the sales of goods or services by a company during a specific period.
  • Laboratorio Reig Jofre, S.A. Revenue for the year ending December 31, 2022 was USD 290.11 M, a 7.88% change year over year.
  • Laboratorio Reig Jofre, S.A. Revenue for the year ending December 31, 2021 was USD 268.91 M, a -4.32% change year over year.
  • Laboratorio Reig Jofre, S.A. Revenue for the year ending December 31, 2020 was USD 281.06 M, a 25.09% change year over year.
  • Laboratorio Reig Jofre, S.A. Revenue for the year ending December 31, 2019 was USD 224.68 M, a 8.78% change year over year.
Key data
Date Revenue Gross Profit Operating Income EBIT
Market news
Loading...
MCE: RJF.MC

Laboratorio Reig Jofre, S.A.

CEO Mr. Ignasi Biosca Reig
IPO Date Nov. 29, 2002
Location Spain
Headquarters Gran Capita, 10
Employees 1,331
Sector Health Care
Industries
Description

Laboratorio Reig Jofre, S.A., a pharmaceutical company, researches, develops, manufactures, and markets pharmaceutical products and food supplements. The company offers prescription medicines, OTCs, medical devices, and cosmetics. Its products include pharmaceutical technologies products, such as antibiotics, and injectable and other products; specialty pharmacare products, which include skin, hair, and nail health, joint health and pain, women's health, respiratory/ENT, and pediatrics; and consumer healthcare products under the Forté Pharma brand. The company also provides CDMO and CMO services. It sells its products directly in 7 countries and through business partners in approximately 70 countries. The company was founded in 1929 and is based in Sant Joan Despí, Spain. Laboratorio Reig Jofre, S.A. is a subsidiary of Reig Jofre Investments SL.

Similar companies

PHM.MC

Pharma Mar, S.A.

USD 77.86

1.89%

ROVI.MC

Laboratorios Farmaceuticos Rovi, S.A.

USD 59.78

-0.59%

FAE.MC

Faes Farma, S.A.

USD 3.46

-1.45%

ALM.MC

Almirall, S.A.

USD 8.60

3.71%

ORY.MC

Oryzon Genomics S.A.

USD 1.51

-0.07%

StockViz Staff

January 15, 2025

Any question? Send us an email